CRL

N/A

Charles River Laboratories Inte

Healthcare · Rank #495 · Analyzed Oct 18, 2026

$300.15

Current Price

⚠️ Unverified — fails data-quality checks

This ticker did not clear our Definition of Done, so its valuation is shown for transparency but should not be trusted:

• Intrinsic value not computed
• Insufficient data to rate
• <2 valuation methods computed

$0.00

Intrinsic Value

-88.9%

Upside/Downside

0/10

Score

0.5/5

Quality

Analysis Summary

Valuation Consensus0/1 methods agree

Quality Score0.5/5.0

Framework RatingINSUFFICIENT DATA

Price vs Intrinsic ValueOvervalued by 88.9%

Fair Value Range

Low$33.20

Base (IV)$0.00

High$33.20

Entry Points

Conservative$23.24

Moderate$33.20

Aggressive$23.24

⚠️ Warnings

DCF discarded: negative profit margins
Insufficient data: fewer than 2 valuation methods

Quality & Moat Breakdown

Return on Equity-7.5% → 0/1.0

Debt LevelD/E 105 → 0/1.0

Revenue QualityGrowth -1.1%, margin Δ+0.2% +recovery → 0.5/1.0

Moat Strength1.0/5 → 0/1.0

Profit Margins-6.0% → 0/1.0

Methodology

This analysis uses a unified valuation framework combining three methods, Discounted Cash Flow (3-scenario), Earnings Power Value, and Asset Valuation, with a quality scoring overlay. A stock needs 2/3 valuation methods to agree and a quality score ≥ 3.5/5 for a BUY rating.

Learn how this framework works →

This is a personal analysis tool, not financial advice. Do your own research before making investment decisions.